Psoriatic Arthritis

Adults with active psoriatic arthritis taking bimekizumab saw significant improvements in joint symptoms and skin clearance compared with those taking placebo, UCB announced in a press release.

PHILADELPHIA — Patients with psoriatic arthritis who have depression may perceive their disease differently compared with patients without depression which may make achievement of low disease activity or remission more challenging.

PHILADELPHIA — While over half of referrals generated by results from a home-screening survey for psoriatic arthritis were deemed appropriate, the rate of an actual diagnosis was low, according to results of a study.

Understanding the mechanism of action by which psoriatic arthritis treatment works and taking a patient’s lifestyle into account can benefit clinicians treating patients with the condition, said Philip J. Mease, MD, of the Swedish Medical Center in Seattle and the University of Washington.

Patients with psoriatic arthritis who receive tofacitinib demonstrate “sustained improvements” in dactylitis compared with those who did not receive tofacitinib, according to data published in BMC Rheumatology.

PHILADELPHIA — Guided online participation in a wellness program was preferred over in-person or self-guided programs among patients with psoriatic arthritis, according to a poster presentation at ACR Convergence 2022.

PHILADELPHIA — The efficacy of COVID-19 vaccinations is similar in patients with psoriatic disease compared non-psoriatic controls, according to data presented at ACR Convergence 2022.

PHILADELPHIA — Despite frequent reports of poor sleep quality among patients with psoriatic arthritis, many do not receive treatment, according to findings from a cross-sectional study reported at ACR Convergence 2022.

PHILADELPHIA — Non-Hispanic white patients are overrepresented while Black and Hispanic patients are underrepresented in pivotal psoriatic arthritic clinical trials, according to data presented at ACR Convergence 2022.

PHILADELPHIA — Among patients with psoriatic arthritis, izokibep exhibited clinically significant improvements across various patient reported outcomes, according to findings presented at ACR Convergence 2022.